Patents Assigned to SYSTIMMUNE, INC.
  • Non-natural amatoxin-type antibody conjugate
    Patent number: 12268752
    Abstract: Disclosed is a non-natural amatoxin-type antibody conjugate, said conjugate similar to the natural amatoxin is linked to a biopharmaceutically acceptable salt with a target biomolecule so as to obtain stability in blood plasma, and efficiently kill tumor cells in cells.
    Type: Grant
    Filed: August 18, 2018
    Date of Patent: April 8, 2025
    Assignee: SYSTIMMUNE, INC.
    Inventors: Yi Zhu, Jie Li, Yongguo Yu, Weijia Liu, Shi Zhuo
  • Guidance and Navigation Control proteins and method of making and using thereof
    Patent number: 12029761
    Abstract: The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: July 9, 2024
    Assignee: SYSTIMMUNE, INC.
    Inventors: Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Camilla Wang, Zeren Gao, Hui Huang
  • Tri-specific antibodies
    Patent number: 11649286
    Abstract: The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 16, 2023
    Assignees: SYSTIMMUNE INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
    Inventors: Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie K. Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Zeren Gao
  • Anti-CD3 antibodies and methods of making and using thereof
    Patent number: 11535667
    Abstract: The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 27, 2022
    Assignees: SYSTIMMUNE, INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
    Inventors: Ole Olsen, Phil Tan, Dong Xia, David Jellyman, Brian Kovacevich, Bill Brady, Blair Renshaw, Zeren Gao, Yi Zhu
  • Anti-ROR1 antibodies and methods of making and using thereof
    Patent number: 11518815
    Abstract: The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 6, 2022
    Assignees: SYSTIMMUNE, INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
    Inventors: Ole Olsen, Phil Tan, Dong Xia, David Jellyman, Brian Kovacevich, Bill Brady, Blair Renshaw, Zeren Gao, Yi Zhu
  • Anti-PD-1 antibodies and methods of making and using thereof
    Patent number: 11466084
    Abstract: The application provides anti-PD-1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 11, 2022
    Assignee: SYSTIMMUNE, INC.
    Inventors: Brian Kovacevich, Dong Xia, Anne E. Jensen, Jonathan K. Fallen, Blair Renshaw, Jeffrey B. Adamo, Phil Tan, Zeren Gao, Yi Zhu
  • Bispecific tetravalent antibodies and methods of making and using thereof
    Patent number: 10919977
    Abstract: A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: February 16, 2021
    Assignees: SYSTIMMUNE, INC., Sichuan Baili Pharmaceutical Co. Ltd.
    Inventors: Zeren Gao, Phil Tan, Brian R. Kovacevich, Blair R. Renshaw, Jeffrey B. Adamo, Nga Sze Amanda Mak, Shi Zhuo, Lan Chen, Yi Zhu